FDA-Cleared Powered Microneedling Devices: SkinPen vs. Exceed vs. SkinStylus

Mechanical microneedling has evolved from a simple aesthetic skin-needling method into a highly regulated, clinically validated category of medical devices. By creating thousands of microscopic channels in the skin, these devices trigger the body's natural wound-healing cascade, stimulating new collagen and elastin production without thermal damage. However, the rise of unregulated and at-home pens has created significant confusion in both consumer and clinical markets. For professional providers and patients alike, understanding which devices are actually cleared by the U.S. Food and Drug Administration (FDA) is essential for patient safety, clinical efficacy, and legal compliance.

The three leading FDA-cleared powered microneedling devices are the SkinPen Precision (Crown Aesthetics), Exceed (Mt. Derm GmbH), and SkinStylus SteriLock (Esthetic Medical). SkinPen was the first device cleared under the De Novo pathway (DEN160029) in 2018. Exceed was cleared in 2018 (K180778) as the first dual-indication device for both acne scars and facial wrinkles. SkinStylus SteriLock received clearance in 2020 (K200044) with a design that allows the motor unit to be completely autoclave-sterilized. All three devices are cleared for treating facial acne scars in adults, but they differ in needle count, speed settings, depth range, and sterilization workflows.

SkinPen Precision (first De Novo clearance in 2018), Exceed (cleared for acne scars and wrinkles in 2018), and SkinStylus SteriLock (cleared in 2020 with autoclave-sterilizable motor) are the leading FDA-cleared powered microneedling devices under product code QAI.

To help clinicians and advanced patients evaluate these systems, this guide compares their regulatory clearances, mechanical specifications, sterilization protocols, and real-world safety data from the FDA's Manufacturer and User Facility Device Experience (MAUDE) database.

---

What are the FDA clearances and product codes for SkinPen, Exceed, and SkinStylus?

Before 2018, the FDA did not have a dedicated product code or regulatory pathway for motorized skin-needling pens. Many older devices were sold under general clearances or without explicit clinical needling indications. On March 1, 2018, the FDA established a new regulatory classification under product code QAI (defined as a "powered microneedle device for aesthetic use") by granting De Novo clearance to the SkinPen Precision. This classification established Class II medical device requirements for all subsequent systems, requiring manufacturers to demonstrate clinical safety, biocompatibility, and strict sterilization controls.

Currently, the FDA's 510(k) database lists exactly 26 clearances registered under the product code QAI. This is a highly selective list compared to other aesthetic device categories. The regulatory histories of the top three systems demonstrate how the pathway has expanded:

1. SkinPen Precision (Crown Aesthetics / Bellus Medical)

SkinPen Precision established the baseline for the QAI product code. It received De Novo clearance under number DEN160029 on March 1, 2018. The original indication was limited to improving the appearance of facial acne scars in adults aged 22 years or older.

Crown Aesthetics subsequently sought to expand these indications. Under clearance K202243 (cleared April 2, 2021), SkinPen became the first mechanical needling device cleared for the treatment of wrinkles of the neck. Later clearances, such as K220506 (March 7, 2022), refined the system's software and cartridge specifications to ensure consistent motor speed under load.

2. Exceed (MT.DERM GmbH)

The Exceed system, manufactured by the German engineering firm MT.DERM, received its primary FDA 510(k) clearance under K180778 on September 7, 2018. While SkinPen was the first device cleared, Exceed was the first to enter the market with a dual indication.

Its clearance officially covered both the treatment of moderate-to-severe facial acne scars in adults (K182407) and the treatment of facial wrinkles (K180778). This dual clearance was supported by clinical trials showing a statistically significant reduction in wrinkles without the downtime associated with energy-based devices.

3. SkinStylus SteriLock MicroSystem (Esthetic Medical, Inc.)

SkinStylus entered the FDA-cleared tier with the clearance of its SteriLock MicroSystem (Model MP1209SL) under K200044 on April 10, 2020. Esthetic Medical focused its design on sterile processing.

The device received subsequent clearances, including K231073 and the recent K253002 (cleared on February 19, 2026). SkinStylus is cleared for the improvement of facial acne scars in adults with Fitzpatrick skin types I, II, and III. Additionally, it has a unique cleared indication for treating surgical or traumatic hypertrophic scars on the abdomen in adults, making it highly versatile for body treatments.

---

How do the design specifications and needle profiles compare?

While all three devices achieve the same basic clinical objective, they differ fundamentally in their engineering, motor design, needle cartridges, and clinical workflows. Understanding these mechanical profiles helps explain how the systems handle skin resistance and maintain patient comfort.

Needle Cartridge Engineering and Configuration

The design of the disposable needle cartridge is the primary variable affecting skin penetration and tissue trauma:

• SkinPen Precision: Uses a proprietary, single-use cartridge containing 14 surgical-grade stainless steel needles. The cartridge features a patented double-walled vacuum lock that prevents fluid ingress into the motor unit. The needle gauge is 32G, which minimizes patient discomfort. The linear motor drive delivers 100% vertical reciprocating motion to prevent epidermal scratching or tearing.
• Exceed: Employs a 12-needle cartridge arranged in a circular configuration. The needles are made from high-precision, surgical-grade stainless steel. MT.DERM designed the cartridge with a tilting needle plate that adapts to the contours of the skin, ensuring that the needles enter perpendicularly even when the handpiece is held at an angle.
• SkinStylus: Utilizes a 12-needle cartridge design. Like the others, it operates with strict vertical reciprocating motion. The needles are spaced to allow uniform density of micro-channels.

Speed Settings and Power Sources

A consistent, high-torque motor is necessary to prevent the needles from catching or "dragging" through the skin, especially when treating dense scar tissue:

• SkinPen Precision: Powered by a rechargeable lithium-ion battery. The cordless design provides excellent mobility. The microprocessor maintains a fixed speed of approximately 7,000 RPM (translating to over 1,600 micro-channels per second) regardless of battery charge level or skin resistance.
• Exceed: A corded system powered by a dedicated control console. By relying on a direct power supply, the system eliminates battery fade. The control panel allows the operator to select from multiple speed settings (ranging from 50 to 150 strokes per second), allowing customized treatment based on skin thickness and patient tolerance.
• SkinStylus: Offers dual-operation capability. It can be run as a cordless device via rechargeable battery sleeves or corded for continuous power. The system operates at speeds up to 7,200 RPM, maintaining high torque to prevent stalling in thick, fibrous tissue.

Depth Adjustment Mechanics

Needle depth determines which skin layer is targeted. Dermal collagen induction requires reaching the papillary and reticular dermis, whereas scar tissue remodeling often requires deeper penetration:

• SkinPen Precision: The depth is adjustable from 0.25 mm to 2.5 mm in increments of 0.25 mm. The adjustment ring is on the handpiece, allowing the provider to modify the depth mid-treatment as they move between thin skin (e.g., forehead) and thicker skin (e.g., cheeks).
• Exceed: Limits its maximum depth to 1.5 mm. MT.DERM engineered the device to target the dermis precisely without entering deeper subcutaneous layers. Because the FDA clearances for acne scars and wrinkles are achieved within this range, the 1.5 mm limit acts as a mechanical safety guard against unintentional deep needling.
• SkinStylus: Offers an adjustment range from 0.25 mm up to 2.5 mm. When treating abdominal hypertrophic scars under its cleared indication, the deeper 2.5 mm setting is particularly useful for breaking up thick, deep collagen bands.

Sterilization and Infection Control Workflows

Cross-contamination is the most critical safety risk associated with motorized skin needling. Because microneedling generates aerosolized blood and body fluids, the interior of the device handpiece can act as a reservoir for pathogens if not properly isolated.

• The Sheath Model (SkinPen & Exceed): Because the electric motors and internal drivetrains of the SkinPen and Exceed handpieces cannot survive steam sterilization (autoclaving), these systems rely on a combination of physical barriers and chemical disinfection.
  • SkinPen uses a single-use protective sheathing that covers the entire handpiece, coupled with a sealed needle cartridge that contains a backflow prevention membrane. After the treatment, the sheath is discarded, and the handpiece is disinfected using clinical-grade wipes (such as CaviWipes).
  • Exceed utilizes a similar protocol, employing custom-fit disposable plastic barriers over the handpiece and requiring strict post-treatment sanitization.
• The Autoclavable Model (SkinStylus SteriLock): Esthetic Medical designed the SkinStylus to address the limitations of chemical disinfection. The SteriLock system features a modular design where the outer nose cone and the entire motor housing sleeve can be separated from the internal battery/drive unit. These detached components are made from medical-grade anodized aluminum and are fully validated to undergo autoclave steam sterilization at 132°C (270°F) for 4 minutes (or 121°C for 30 minutes). This provides a surgical-level sterilization loop that eliminates the risk of cross-contamination from the handpiece shell.

---

What does the openFDA MAUDE database show for microneedling adverse events?

Evaluating the safety profile of medical devices requires looking beyond manufacturer-sponsored clinical trials to post-market surveillance data. The FDA's MAUDE database collect reports of adverse events, injuries, and device malfunctions submitted by manufacturers, healthcare providers, and consumers.

For product code QAI (Powered Microneedle Device), the database contains exactly 58 adverse event reports. That is an exceptionally low number compared to thermal energy-based devices (such as fractional lasers or radiofrequency systems), which frequently accumulate hundreds or thousands of reports due to burn risks. One important caveat: the single largest contributor to this code is not a microneedle pen at all — the Ellacor micro-coring system dominates the count — so the headline total overstates the reporting rate for conventional pens.

[QAI Product Code Adverse Event Breakdown (n = 58, counted by brand name)]
├── Ellacor micro-coring system (Cytrellis / Merz): ~28 reports (~48%)
├── SkinPen (Crown / Bellus Medical): ~12 reports (~21%)
└── All other pens + unspecified (Exceed, SkinStylus, Eclipse, Dr. Pen, etc.): ~18 reports (~31%)

Counted by brand name (the method that matches our dedicated microneedling MAUDE analysis), the 58 reports break down as follows:

• Ellacor micro-coring system (Cytrellis, now Merz): ~28 reports — the single largest contributor. Ellacor removes small columns of tissue rather than creating fine needle punctures, so its report volume is not representative of conventional pen-based microneedling.
• SkinPen (Crown Laboratories, formerly Bellus Medical): ~12 reports. Because SkinPen is the most widely used powered pen in the U.S., a higher absolute count is expected from market share alone and from more robust mandatory manufacturer reporting.
• Exceed, SkinStylus SteriLock, Eclipse MicroPen, and other conventional pens: only a handful of reports each — in several cases zero in the current snapshot — which supports a low overall reporting rate for mechanical needle-based microneedling.

Interpretation of MAUDE Data

When analyzing MAUDE reports for microneedling devices, it is important to apply standard public health caveats:

1. Passive Surveillance Limits: MAUDE relies on voluntary reporting from clinicians and consumers, alongside mandatory reporting from manufacturers when they become aware of an event. Under-reporting is common, particularly for minor side effects.
2. No Causality Proof: A report in the database does not prove that the device caused the adverse event. User error, improper patient selection, poor post-care hygiene, or concurrent treatments (such as applying non-sterile topicals immediately after needling) are often the primary drivers.
3. Reporting Bias: Larger, more established brands (like SkinPen) typically have more robust compliance departments and higher market penetration, which naturally leads to a higher volume of reported events compared to smaller brands.

Analysis of Common Adverse Event Types in MAUDE

The 58 reports under product code QAI reveal specific patterns of clinical injury:

• Epidermal Scratches and Lacerations: Several reports describe linear scratches on the patient’s skin. In these cases, the primary cause is typically the operator moving the handpiece across the skin before the needles have fully retracted, or using a bent needle cartridge. It highlights the importance of using high-torque motors that maintain vertical movement under load.
• Persistent Erythema and Swelling: A subset of reports notes redness and swelling that persisted for more than two weeks. In healthy patients, normal post-treatment erythema resolves within 24 to 72 hours. Prolonged inflammation is frequently linked to treating patients with active eczema, rosacea, or compromised skin barriers.
• Allergic Contact Dermatitis (Granuloma Formation): The most serious reports involve patients developing firm nodules (granulomas) under the skin. Clinicians have determined that this is almost never caused by the sterile stainless steel needles. Instead, it occurs when non-sterile, immunogenic substances (such as non-approved vitamin C serums, hyaluronic acid formulations containing preservatives, or makeup) are applied immediately after needling. Because microneedling bypasses the stratum corneum, any topical applied within 24 hours of treatment can act as a foreign body, triggering an immune response.
• Superficial Infections: Isolated reports note bacterial outbreaks (such as Staphylococcus aureus or Cutibacterium acnes) following treatment. These are typically traced to poor post-care compliance (e.g., touching the face with dirty hands or reusing makeup brushes) rather than handpiece cross-contamination.

---

Clinical Trial Efficacy and Safety Profile

To achieve De Novo or 510(k) clearance under product code QAI, each manufacturer had to submit prospective clinical data demonstrating that the device improves skin contour without causing long-term harm.

SkinPen Precision Clinical Data

The pivotal clinical trial for SkinPen Precision evaluated its safety and efficacy in treating facial acne scars:

• Study Design: A multi-center, prospective, single-arm clinical trial involving 90 subjects.
• Treatment Protocol: Subjects received 3 treatments spaced 4 weeks apart. The needle depth was adjusted based on the anatomical zone, up to 2.5 mm.
• Efficacy Outcomes: Blinded dermatologists evaluated the subjects' skin using the Quantitative Global Aesthetic Improvement Scale (GAIS). At 12 weeks post-final treatment, 90% of subjects showed an improvement in the appearance of their acne scars.
• Safety Profile: The most common side effects were transient erythema, tightness, and mild peeling, all of which resolved within 3 to 4 days. No serious adverse events, scarring, or hyperpigmentation changes were reported.

Exceed Clinical Data

MT.DERM submitted clinical data to support both of its cleared indications. As the first device cleared with a dual indication — facial acne scars (under K182407) and facial wrinkles (under K180778) — Exceed's regulatory submissions demonstrated meaningful improvements in scar texture and wrinkle depth on blinded grading scales, with a safety profile limited to transient erythema, edema, and pinpoint bleeding. The 1.5 mm maximum needle depth was validated as sufficient to induce neocollagenesis in the reticular dermis without entering the subcutaneous fat layer.

SkinStylus Clinical Data

SkinStylus's clearances were supported by testing focused on scar remodeling:

• Hypertrophic Scar Study: Clinical evaluations of the system's performance on thick, fibrous scars on the abdomen. By needling at depths up to 2.5 mm, the device successfully remodeled dense, disorganized collagen bundles without inducing further hypertrophic growth.
• Skin of Color Safety: The clinical submissions showed that when appropriate settings (moderate depth, conservative passes) are used, the mechanical needling mechanism carries a minimal risk of Post-Inflammatory Hyperpigmentation (PIH) in Fitzpatrick skin types IV–VI, contrasting with energy-based resurfacing devices.

---

Frequently Asked Questions

Is Dr. Pen FDA-cleared for clinical microneedling?

No. Dr. Pen devices are not FDA-cleared under product code QAI for clinical microneedling.

Many Dr. Pen models are sold online directly to consumers. Because they bypass Class II regulatory controls, they carry significant safety risks:

• Lack of Quality Control: Unregulated pens often exhibit irregular needle lengths, rough needle tips, or unstable motor speeds, which can cause epidermal tearing, bleeding, and micro-scarring.
• Cross-Contamination Risk: Dr. Pen cartridges typically lack a sealed backflow membrane. During use, blood and interstitial fluid can be drawn into the handpiece barrel via capillary action. If the handpiece is reused on another patient, this fluid can contaminate the new cartridge, risking the transmission of bloodborne pathogens (such as Hepatitis B, Hepatitis C, and HIV).
• Legal and Insurance Risks: Operating a non-FDA-cleared device in a clinical setting is a violation of professional licensing standards. If a patient experiences an adverse event (such as infection or scarring) from a non-cleared device, the practice's malpractice insurance policy will typically deny coverage.

How do the sterilization protocols differ between SkinPen and SkinStylus?

The core difference lies in the sterilization boundary of the handpiece. Because the motor and drivetrain of the SkinPen Precision are integrated into a single-unit housing that cannot withstand high-pressure steam, the device relies on a hygiene barrier protocol:

1. A disposable, single-use plastic sheath is wrapped around the handpiece before the sterile cartridge is attached.
2. The needle cartridge features a sealed gaskets to prevent fluid backflow.
3. After treatment, the sheath is discarded, and the handpiece is hand-sanitized using chemical disinfectants.

In contrast, the SkinStylus SteriLock uses a validated autoclaving protocol:

1. The outer sleeve and nose cone of the handpiece are made of medical-grade aluminum.
2. After treatment, these components are detached from the internal motor drive.
3. The outer sleeve and nose cone are placed in an autoclave and steam-sterilized at 132°C (270°F) for 4 minutes, killing all bacterial spores, viruses, and pathogens.
4. The internal, non-autoclavable drive unit is wiped down chemically, but it never comes into contact with the patient's skin or fluids due to the sterile metal sleeve.

---

Clinical Selection Criteria: How to Choose a Device

For an aesthetic practice, selecting the right microneedling system depends on patient demographics, treatment indications, and clinic workflow:

• Choose SkinPen Precision if: Your practice requires a cordless device with high brand recognition. SkinPen's De Novo status and extensive consumer marketing make it an easy choice for patient acquisition. Its cordless design is ideal for multi-room clinics where mobility is key.
• Choose Exceed if: Your practice focuses heavily on facial rejuvenation and anti-aging treatments. The dual clearance for wrinkles and acne scars provides a broad regulatory scope. The console-powered, corded design ensures consistent torque without the need to manage battery charging cycles.
• Choose SkinStylus SteriLock if: Your clinic prioritizes strict sterile processing standards or performs body treatments. The steam-autoclavable motor sleeve offers the highest level of cross-contamination prevention. The 2.5 mm depth capacity and clearance for abdominal hypertrophic scars make it the preferred system for scar remodeling clinics.

---

Sources

• FDA De Novo Classification Summary: SkinPen Precision System (DEN160029). March 1, 2018. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/denovo.cfm?id=DEN160029
• FDA 510(k) Premarket Notification: Exceed Microneedling Device (K180778). September 7, 2018. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf510k/510k.cfm?id=K180778
• FDA 510(k) Premarket Notification: SkinStylus SteriLock MicroSystem (K200044). April 10, 2020. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf510k/510k.cfm?id=K200044
• FDA 510(k) Premarket Notification: SkinStylus SteriLock MicroSystem Model MP1209SL (K253002). February 19, 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf510k/510k.cfm?id=K253002
• FDA 510(k) Premarket Notification: SkinPen Precision System (K220506). March 7, 2022. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf510k/510k.cfm?id=K220506
• FDA MAUDE Database Search for Product Code "QAI". Data extract June 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm
• FDA Aesthetic Cosmetic Devices Index: Powered Microneedle Devices. Updated October 15, 2025. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devices
• American Academy of Dermatology (AAD): Microneedling for Scars and Aging Skin. https://www.aad.org/public/cosmetic/scars-stretch-marks/microneedling-scars-aging
• FDA 510(k) Premarket Notification: Exceed Microneedling Device — Acne Scar Indication (K182407). July 19, 2019. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf510k/510k.cfm?id=K182407